Cancer vaccines have been widely recognized as one of the greatest achievements in cancer prevention due to their high effectiveness in preventing morbidity and mortality. Creative Biolabs is dedicated to pre-clinical development for cancer vaccine including animal models for vaccine, pre-clinical pharmacology for vaccine and pre-clinical toxicology of vaccines.
Creative Biolabs has a wide range of services and expertise to help vaccine developers to develop a comprehensive strategy covering pre-clinical development to clinical trials. Toxicological assessments of multiple species can be designed, performed, and documented through wide range routes of administration. Our toxicological studies offer insights into safety data required for vaccine development. In order to meet the requirements of preclinical surveillance in a GLP compliant environment, we offer CDC-approved quarantine facilities with Biosafety Level (BSL)-2.
For autologous DC vaccines, human HLA specific therapies, etc., to get a better understanding about the information of the antigen, construct, expression and tissue distribution, etc., we offer a variety of studies including mRNA expression, tissue cross-reactivity studies of mAb against the Ag and genomic database searching. For individual toxicological studies, please visit the following buttons to learn more.
To assess the toxicology, we can perform various assays to monitor the following biomarkers or endpoints.
With an experienced scientist, we have established the following general considerations for vaccine toxicological assessment:
With the expertise of pre-clinical toxicological and specific animal models, Creative Biolabs can assist in performing the most appropriate toxicological studies to assess the safety data and help our clients to develop better vaccines. For more detailed information, please visit our website or contact us directly.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE